Chronic pain, including chronic orofacial pain, remains unsuccessfully treated in a large number of patients. Furthermore, the loss of analgesic efficacy with chronic administration of frontline analgesic drugs, such as morphine, severely limits their use. Recent data strongly suggest that spinal cord glia (astrocytes and microglia) oppose the analgesic effects of morphine, through the release of proinflammatory cytokines: tumor necrosis factor (TNF), interleukin-1 (IL1) &interleukin-6 (IL6). While as yet unexplored, this raises the possibility that glial activation by clinically relevant opioid analgesics may be broad in scope, rather than a phenomenon restricted to morphine. Therefore, (a) clinical pain control may currently be hindered by opioid-induced glial activation &, (b) if this is true, clinical pain control could be improved by finding ways to prevent or circumvent the effects of glial activation by opioid analgesics. Therefore, the aims of the proposal are to determine whether: (I) clinically relevant opioid analgesics, in general, induce proinflammatory cytokines in trigeminal nuclei, and also in spinal cord under normal (sham) &/or neuropathic (chronic constriction injury;CCI) pain conditions. Further, whether an anti-inflammatory cytokine will """"""""unmask"""""""" analgesia following chronic opioid administration. The potential for chronically enhancing analgesic efficacy by chronic co-administration of an anti-inflammatory cytokine will also be explored. (II) the induction of spinal proinflammatory cytokines by morphine &other opioids is mediated, in part, via actions of their common, active metabolites (M6G or M3G);and (III) the elevated production/release of trigeminal and spinal proinflammatory cytokines induced by opioid pharmacotherapies is mediated via classical opioid receptors. Moreover, whether selective mu, delta &kappa receptor agonists mimic the effects of clinically relevant analgesics. Where feasible, sciatic CCI will be replaced by CCI of the infraorbital nerve &assessment of orofacial mechanical allodynia &thermal hyperalgesia. Together these studies will provide novel insights into the actions of opioid analgesics at both trigeminal &spinal sites, &will explore the potential for using anti-inflammatory cytokines as a means of potentiating the magnitude &duration of analgesia to relieve normal &neuropathic pain. If successful, these studies will lead to development of novel adjunct therapies for improving clinical pain control by controlling the negative consequences of opioid-induced glial activation.

Agency
National Institute of Health (NIH)
Institute
National Institute of Dental & Craniofacial Research (NIDCR)
Type
Research Project (R01)
Project #
3R01DE017782-03S2
Application #
7840785
Study Section
Special Emphasis Panel (ZDE1-GH (50))
Program Officer
Kusiak, John W
Project Start
2009-06-01
Project End
2010-05-31
Budget Start
2009-06-01
Budget End
2010-05-31
Support Year
3
Fiscal Year
2009
Total Cost
$21,210
Indirect Cost
Name
University of Colorado at Boulder
Department
Psychology
Type
Schools of Arts and Sciences
DUNS #
007431505
City
Boulder
State
CO
Country
United States
Zip Code
80309
Grace, Peter M; Maier, Steven F; Watkins, Linda R (2015) Opioid-induced central immune signaling: implications for opioid analgesia. Headache 55:475-89
Hutchinson, Mark R; Watkins, Linda R (2014) Why is neuroimmunopharmacology crucial for the future of addiction research? Neuropharmacology 76 Pt B:218-27
Grace, P M; Ramos, K M; Rodgers, K M et al. (2014) Activation of adult rat CNS endothelial cells by opioid-induced toll-like receptor 4 (TLR4) signaling induces proinflammatory, biochemical, morphological, and behavioral sequelae. Neuroscience 280:299-317
Bastos, Leandro F S; Godin, Adriana M; Zhang, Yingning et al. (2013) A minocycline derivative reduces nerve injury-induced allodynia, LPS-induced prostaglandin E2 microglial production and signaling via toll-like receptors 2 and 4. Neurosci Lett 543:157-62
Lewis, Susannah S; Hutchinson, Mark R; Zhang, Yingning et al. (2013) Glucuronic acid and the ethanol metabolite ethyl-glucuronide cause toll-like receptor 4 activation and enhanced pain. Brain Behav Immun 30:24-32
Hutchinson, M R; Northcutt, A L; Hiranita, T et al. (2012) Opioid activation of toll-like receptor 4 contributes to drug reinforcement. J Neurosci 32:11187-200
Wieseler, Julie; Sprunger, David; Ellis, Amanda et al. (2012) Indwelling supradural catheters for induction of facial allodynia: surgical procedures, application of inflammatory stimuli, and behavioral testing. Methods Mol Biol 851:99-107
Lewis, Susannah S; Loram, Lisa C; Hutchinson, Mark R et al. (2012) (+)-naloxone, an opioid-inactive toll-like receptor 4 signaling inhibitor, reverses multiple models of chronic neuropathic pain in rats. J Pain 13:498-506
Loram, Lisa C; Sholar, Paige W; Taylor, Frederick R et al. (2012) Sex and estradiol influence glial pro-inflammatory responses to lipopolysaccharide in rats. Psychoneuroendocrinology 37:1688-99
Loram, Lisa C; Grace, Peter M; Strand, Keith A et al. (2012) Prior exposure to repeated morphine potentiates mechanical allodynia induced by peripheral inflammation and neuropathy. Brain Behav Immun 26:1256-64

Showing the most recent 10 out of 32 publications